胆汁酸在肝肠循环中的作用及中药参与其调控的相关机制

叶倩伶; 王明刚; 毛德文; 蒋海南

doi:10.3969/j.issn.1001-5256.2020.11.050

胆汁酸在肝肠循环中的作用及中药参与其调控的相关机制

DOI: 10.3969/j.issn.1001-5256.2020.11.050

1. 广西中医药大学第一临床医学院
2. 广西中医药大学第一附属医院肝病科

基金项目:

国家自然科学基金项目（81704021,81960841）；广西自然科学基金（2017GXNSFBA198200,2018GXNSFAA281047）;广西自然科学基金创新研究团队项目（2018GXNSFGA281002）；广西中医肝病临床医学研究中心（桂科AD17129001）；广西高校中青年教师基础能力提升项目（KY2016YB208）；广西中医药大学硕士研究生科研创新项目（YCSZ2020025）；

详细信息

中图分类号: R259
计量
- 文章访问数: 889
- HTML全文浏览量: 31
- PDF下载量: 109
- 被引次数: 0
出版历程
- 收稿日期: 2020-04-15
- 出版日期: 2020-11-20

Role of bile acids in enterohepatic circulation and mechanism of action of traditional Chinese medicine in regulating bile acids

The First Clinical Medical College,Guangxi University of Chinese Medicine
Department of Hepatology,The First Affiliated Hospital of Guangxi University of Chinese Medicine

Research funding:

摘要

摘要:
胆汁酸在肝脏中产生,是胆固醇分解代谢的最终产物,具有广泛的生物学效应。就胆汁酸的合成、转运、代谢,及其通过肝肠循环调控肝脏细胞及免疫方面的研究进展、中医药在调控胆汁酸这一领域的研究现状作一综述,深入了解胆汁酸影响肠道菌群及肝脏功能的相关机制,拓展其调控机制的认识,探索中医药对胆汁酸调节的作用机制及途径,为从调控胆汁酸途径防治肝脏相关系统性疾病提供新思路。
- 胆汁酸类和盐类 /
- 胃肠道微生物组 /
- 中草药
Abstract:
Bile acids( BAs) are produced in the liver and are the final product of cholesterol catabolism,with a wide range of biological effects. This article reviews the research advances in the synthesis,transport,and metabolism of BAs and the role of BAs in regulating hepatocytes and immunity via enterohepatic circulation,as well as the current research on traditional Chinese medicine in the regulation of BAs,in order to further understand the mechanism of action of BAs in affecting intestinal flora and liver function,expand the knowledge of its regulatory mechanism,explore the mechanism of action of traditional Chinese medicine and related pathways in regulating BAs,and provide new ideas for the prevention and treatment of liver-related systemic diseases by regulating BAs.
- bile acids and salts /
- gastrointestinal microbiome /
- drugs,Chinese herbal

HTML全文

参考文献(46)

[1]SONG YN,ZHANG GB,LU YY,et al.Huangqi decoction alleviates dimethylnitrosamine-induced liver fibrosis:An analysis of bile acids metabolic mechanism[J].J Ethnopharmacol,2016,189:148-156.

[2]ABT MC,MCKENNEY PT,PAMER EG.Clostridium difficile colitis:Pathogenesis and host defence[J].Nat Rev Microbiol,2016,14(10):609-620.

[3]XIONG A,YANG F,FANG L,et al.Metabolomic and genomic evidence for compromised bile acid homeostasis by senecionine,a hepatotoxic pyrrolizidine alkaloid[J].Chem Res Toxicol,2014,27(5):775-786.

[4] GUO C,XIE S,CHI Z,et al.Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome[J].Immunity,2016,45(4):944.

[5]ZHANG R,HUANG T,ZHANG Q,et al.Xiaoyan lidan formula amelioratesα-naphthylisothiocyanate-induced intrahepatic cholestatic liver injury in rats as revealed by non-targeted and targeted metabolomics[J].J Pharm Biomed Anal,2020,179:112966.

[6]WANG N,YANG B,ZHANG J,et al.Metabolite profiling of traditional Chinese medicine XIAOPI formula:An integrated strategy based on UPLC-Q-Orbitrap MS combined with network pharmacology analysis[J].Biomed Pharmacother,2020,121:109569.

[7]CHIANG JY.Regulation of bile acid synthesis:Pathways,nuclear receptors,and mechanisms[J].J Hepatol,2004,40(3):539-551.

[8]MERTENS KL,KALSBEEK A,SOETERS MR,et al.Bile acid signaling pathways from the enterohepatic circulation to the central nervous system[J].Front Neurosci,2017,11:617.

[9]MAZER NA,BENEDEK GB,CAREY MC.Quasielastic lightscattering studies of aqueous biliary lipid systems.Mixed micelle formation in bile salt-lecithin solutions[J].Biochemis-try,1980,19(4):601-615.

[10]KUBITZ R,DROGE C,STINDT J,et al.The bile salt export pump(BSEP)in health and disease[J].Clin Res Hepatol Gastroenterol,2012,36(6):536-553.

[11]CHAWLA A,REPA JJ,EVANS RM,et al.Nuclear receptors and lipid physiology:Opening the X-files[J].Science,2001,294(5548):1866-1870.

[12]SAINI SP,SONODA J,XU L,et al.A novel constitutive androstane receptor-mediated and CYP3A-independent pathway of bile acid detoxification[J].Mol Pharmacol,2004,65(2):292-300.

[13]STAUDINGER JL,GOODWIN B,JONES SA,et al.The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity[J].Proc Natl Acad Sci U S A,2001,98(6):3369-3374.

[14]SONG C,HIIPAKKA RA,LIAO S.Selective activation of liver X receptor alpha by 6alpha-hydroxy bile acids and analogs[J].Steroids,2000,65(8):423-427.

[15]MAKISHIMA M,LU TT,XIE W,et al.Vitamin D receptor as an intestinal bile acid sensor[J].Science,2002,296(5571):1313-1316.

[16]FIORUCCI S,DISTRUTTI E.Bile Acid-activated receptors,intestinal microbiota,and the treatment of metabolic disorders[J].Trends Mol Med,2015,21(11):702-714.

[17]DEUTSCHMANN K,REICH M,KLINDT C,et al.Bile acid receptors in the biliary tree:TGR5 in physiology and disease[J].Biochim Biophys Acta Mol Basis Dis,2018,1864(4 Pt B):1319-1325.

[18]COPPLE BL,LI T.Pharmacology of bile acid receptors:Evolution of bile acids from simple detergents to complex signaling molecules[J].Pharmacol Res,2016,104:9-21.

[19]STAELS B,FONSECA VA.Bile acids and metabolic regulation:Mechanisms and clinical responses to bile acid sequestration[J].Diabetes Care,2009,32(Suppl 2):s237-s245.

[20]RIDLON JM,KANG DJ,HYLEMON PB.Bile salt biotransformations by human intestinal bacteria[J].J Lipid Res,2006,47(2):241-259.

[21] CIPRIANI S,MENCARELLI A,CHINI MG,et al.The bile acid receptor GPBAR-1(TGR5)modulates integrity of intestinal barrier and immune response to experimental colitis[J].PLoS One,2011,6(10):e25637.

[22]GADALETA RM,van ERPECUM KJ,OLDENBURG B,et al.Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease[J].Gut,2011,60(4):463-472.

[23]BIAGIOLI M,CARING A,CIPRIANI S,et al.The bile acid receptor GPBAR1 regulates the M1/M2 phenotype of intestinal macrophages and activation of GPBAR1 rescues mice from murine colitis[J].J Immunol,2017,199(2):718-733.

[24]SAKANAKA T,INOUE T,YORIFUJI N,et al.The effects of a TGR5 agonist and a dipeptidyl peptidaseⅣinhibitor on dextran sulfate sodium-induced colitis in mice[J].J Gastroenterol Hepatol,2015,30(Suppl 1):60-65.

[25]RIDLON JM,ALVES JM,HYLEMON PB,et al.Cirrhosis,bile acids and gut microbiota:Unraveling a complex relationship[J].Gut Microbes,2013,4(5):382-387.

[26]KURDI P,KAWANISHI K,MIZUTANI K,et al.Mechanism of growth inhibition by free bile acids in lactobacilli and bifidobacteria[J].J Bacteriol,2006,188(5):1979-1986.

[27]ISLAM KB,FUKIYA S,HAGIO M,et al.Bile acid is a host factor that regulates the composition of the cecal microbiota in rats[J].Gastroenterology,2011,141(5):1773-1781.

[28]KURZ AK,GRAF D,SCHMITT M,et al.Tauroursodesoxycholate-induced choleresis involves p38(MAPK)activation and translocation of the bile salt export pump in rats[J].Gastroenterology,2001,121(2):407-419.

[29]FICKERT P,ZOLLNER G,FUCHSBICHLER A,et al.Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver[J].Gastroenterology,2001,121(1):170-183.

[30]RODRIGUES CM,FAN G,MA X,et al.A novel role for ur-sodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation[J].J Clin Invest,1998,101(12):2790-2799.

[31]AMARAL JD,VIANA RJ,RAMALHO RM,et al.Bile acids:Regulation of apoptosis by ursodeoxycholic acid[J].J Lipid Res,2009,50(9):1721-1734.

[32]SOLA S,CASTRO RE,KREN BT,et al.Modulation of nuclear steroid receptors by ursodeoxycholic acid inhibits TGF-beta1-induced E2F-1/p53-mediated apoptosis of rat hepatocytes[J].Biochemistry,2004,43(26):8429-8438.

[33]MITSUYOSHI H,NAKASHIMA T,SUMIDA Y,et al.Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants[J].Biochem Biophys Res Commun,1999,263(2):537-542.

[34]GULDUTUNA S,ZIMMER G,IMHOF M,et al.Molecular aspects of membrane stabilization by ursodeoxycholate[see comment][J].Gastroenterology,1993,104(6):1736-1744.

[35]CRISPE IN.The liver as a lymphoid organ[J].Annu Rev Immunol,2009,27:147-163.

[36]KIM I,AHN SH,INAGAKI T,et al.Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine[J].J Lipid Res,2007,48(12):2664-2672.

[37]SWANN JR,WANT EJ,GEIER FM,et al.Systemic gut microbial modulation of bile acid metabolism in host tissue compartments[J].Proc Natl Acad Sci U S A,2011,108(Suppl 1):4523-4530.

[38]MENCARELLI A,RENGA B,MIGLIORATI M,et al.The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis[J].J Immunol,2009,183(10):6657-6666.

[39]IRACHETA-VELLVE A,CALENDA CD,PETRASEK J,et al.FXR and TGR5 agonists ameliorate liver injury,steatosis,and inflammation after binge or prolonged alcohol feeding in mice[J].Hepatol Commun,2018,2(11):1379-1391.

[40]FIORUCCI S,BIAGIOLI M,ZAMPELLA A,et al.Bile acids activated receptors regulate innate immunity[J].Front Immunol,2018,9:1853.

[41]LI H,XI Y,XIN X,et al.Salid roside improves high-fat dietinduced non-alcoholic steatohepatitis by regulating the gut microbiota-bile acid-farnesoid X receptor axis[J].Biomed Pharmacother,2020,124:109915.

[42]FENG Y,GAO X,MENG M,et al.Multi-omics reveals the mechanisms of antidepressant-like effects of the low polarity fraction of Bupleuri Radix[J].J Ethnopharmacol,2020,256:112806.

[43]WU DN,GUAN L,JIANG YX,et al.Microbiome and metabonomics study of quercetin for the treatment of atherosclerosis[J].Cardiovasc Diagn Ther,2019,9(6):545-560.

[44]LI N,WANG B,WU Y,et al.Modification effects of SanWei GanJiang Powder on liver and intestinal damage through reversing bile acid homeostasis[J].Biomed Pharmacother,2019,116:109044.

[45]ZHANG CH,XIAO Q,SHENG JQ,et al.Gegen Qinlian Decoction abates nonalcoholic steatohepatitis associated liver injuries via anti-oxidative stress and anti-inflammatory response involved inhibition of toll-like receptor 4 signaling pathways[J].Biomed Pharmacother,2020,126:110076.

[46]WANG GF,LI YY,SHI R,et al.Yinchenzhufu decoction protects against alpha-naphthylisothiocyanate-induced acute cholestatic liver injury in mice by ameliorating disordered bile acid homeostasis and inhibiting inflammatory responses[J].J Ethnopharmacol,2020,254:112672.

施引文献

资源附件(0)

访问统计